Neuphoria Therapeutics (NEUP) Enterprise Value (2020 - 2025)
Neuphoria Therapeutics (NEUP) has disclosed Enterprise Value for 5 consecutive years, with -$22.3 million as the latest value for Q4 2025.
- Quarterly Enterprise Value fell 412.81% to -$22.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$22.3 million through Dec 2025, down 412.81% year-over-year, with the annual reading at -$14.3 million for FY2025, N/A changed from the prior year.
- Enterprise Value for Q4 2025 was -$22.3 million at Neuphoria Therapeutics, down from -$13.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$4.3 million in Q4 2024, with the low at -$24.0 million in Q2 2022.
- Average Enterprise Value over 4 years is -$14.5 million, with a median of -$14.0 million recorded in 2025.
- The sharpest move saw Enterprise Value skyrocketed 49.26% in 2023, then crashed 412.81% in 2025.
- Over 4 years, Enterprise Value stood at -$24.0 million in 2022, then surged by 49.26% to -$12.2 million in 2023, then soared by 64.38% to -$4.3 million in 2024, then plummeted by 412.81% to -$22.3 million in 2025.
- According to Business Quant data, Enterprise Value over the past three periods came in at -$22.3 million, -$13.7 million, and -$14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.